Trabectedin for Patients with Advanced Soft Tissue Sarcoma: A Non-Interventional, Prospective, Multicenter, Phase IV Trial.
STS
non-interventional
prospective
sarcoma
trabectedin
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
25 Oct 2022
25 Oct 2022
Historique:
received:
12
09
2022
revised:
17
10
2022
accepted:
23
10
2022
entrez:
11
11
2022
pubmed:
12
11
2022
medline:
12
11
2022
Statut:
epublish
Résumé
This non-interventional, prospective phase IV trial evaluated trabectedin in patients with soft tissue sarcoma (STS) in real-life clinical practice across Germany. The primary endpoints were progression-free survival (PFS) rates at 3 and 6 months, as defined by investigators. Overall, 128 patients from 19 German sites were evaluated for efficacy and 130 for safety. Median age was 58.5 years (range: 23-84) and leiomyosarcoma was the most frequent histotype (
Identifiants
pubmed: 36358652
pii: cancers14215234
doi: 10.3390/cancers14215234
pmc: PMC9653615
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : PharmaMar (Spain)
ID : 0000
Références
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Cancers (Basel). 2022 Oct 25;14(21):
pubmed: 36358652
Perspect Clin Res. 2010 Oct;1(4):128-33
pubmed: 21350727
Ann Oncol. 2021 Aug;32(8):1034-1044
pubmed: 33932507
Surg Clin North Am. 2008 Jun;88(3):451-81, v
pubmed: 18514694
Lancet Oncol. 2015 Mar;16(3):312-9
pubmed: 25680558
Cancers (Basel). 2021 May 13;13(10):
pubmed: 34068344
Lancet Oncol. 2015 Apr;16(4):406-16
pubmed: 25795406
Cancer. 2019 Aug 1;125(15):2610-2620
pubmed: 31173362
J Clin Oncol. 2016 Mar 10;34(8):786-93
pubmed: 26371143
Drug Des Devel Ther. 2015 Oct 27;9:5785-91
pubmed: 26604682
Int J Oncol. 2013 Jul;43(1):23-8
pubmed: 23652821
Clin Sarcoma Res. 2012 Oct 04;2(1):14
pubmed: 23036164
Mol Cancer Ther. 2010 Aug;9(8):2157-63
pubmed: 20647340
Future Oncol. 2013 Dec;9(12 Suppl):5-10
pubmed: 24195524
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv268-iv269
pubmed: 30285214
J Clin Oncol. 1999 Jan;17(1):150-7
pubmed: 10458228
Invest New Drugs. 2012 Jun;30(3):1193-202
pubmed: 21484250
Cancer Chemother Pharmacol. 2016 Apr;77(4):663-71
pubmed: 26666647
J Clin Oncol. 2007 May 1;25(13):1753-9
pubmed: 17470865
Oncology. 2018;95 Suppl 1:11-20
pubmed: 30554197
Adv Ther. 2022 Apr;39(4):1596-1610
pubmed: 35129790
Ann Oncol. 2014 Sep;25 Suppl 3:iii102-12
pubmed: 25210080
BMC Cancer. 2013 Feb 06;13:64
pubmed: 23388156
Anticancer Drugs. 2017 Nov;28(10):1157-1165
pubmed: 28926423
Cancers (Basel). 2021 Mar 02;13(5):
pubmed: 33801399
J Clin Oncol. 2009 Sep 1;27(25):4188-96
pubmed: 19652065
Eur J Cancer. 2022 Oct;174:261-276
pubmed: 36116829
Eur J Cancer. 2015 Apr;51(6):742-50
pubmed: 25727882